A Clinical Study of Oral Itraconazole Therapy in Dermatophytoses.
- Author:
Jong Yuk YI
;
Baik Kee CHO
- Publication Type:Original Article ; Multicenter Study
- Keywords:
Dermatophytoaes;
Itraconazole;
Multicenter trials
- MeSH:
Drug Eruptions;
Epidermophyton;
Humans;
Itraconazole*;
Lost to Follow-Up;
Microsporum;
Tinea Pedis;
Tinea*;
Trichophyton
- From:Korean Journal of Dermatology
1989;27(3):287-295
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Itraconazole is the first orally active triazole antifungal agent. Authors performed multicenter trials to evaluate the therapeutic effect of itraconazole in dermatophytoses. During 6 months from September, 1988 to February, 1989, 246 patients with dermatophytoses were included in this study. 74 of these cases lost to follow-up and 3 cases developed drug eruption were excluded from analysis of therapeutic efficacy. Duration of therapy were 4 weeks in tinea pedis and tinea manus, and 2 weeks in tinea cruris and tinea corporis. The obtained results were as follows : 1. The everall cure rate of itraconazole in dermatophytoses were 81.3%, and the cure rate in each dermatophytosis were 80.3% in tinea pedis, 100.0% in tines manus, 85.3% in tinea cruris and 68.6% in tinea corporis. 2. The cure rate at two weeks after completion of the therapy(81.3%) was higher than that at the end of the therapy(74.3%). 3. Trichophyton rubrum(70.0%), Trichophyton mentagrophytes(81.3%), Microsporum canis(7.3%) and Epidermophyton floccosum(0.9%) were isolated from 110 cases among the enrolled patients. 4. Seven of the 190 patients experienced adverse effects of the treatment: abdominal discomfort(one); nusea(one); constipation(two); and drug eruption(three). Therefore we impressed that itraconazole is an effective and safe new oral therapeutic: agent for dermatophytoses.
